InfertilityEPFENCT07358468
Association Between Peri-Transfer Endometrial Peristalsis And Live Birth In Modified Natural Cycle Frozen Embryo Transfer: A Prospective Cohort Study
An observational study of Infertility and Endometrial Peristalsis, run by Mỹ Đức Hospital at 2 sites in Vietnam.
Trial summary
The uterus is a dynamic muscular organ that undergoes rhythmic, wave-like contractions known as endometrial peristalsis or endometrial waves. This muscular activity, which is an essential component of natural fertility, presents a nuanced and sometimes contradictory role in the context of assisted reproductive… Read more about this study
- Who is it for?
- Ages 18 to 42 years, women only
- Conditions the study is for
- Infertility, Endometrial Peristalsis, Uterine Contraction
- What is being tested?
- Endometrial peristalsis and hormone measurements
- Type of treatment
- Injection or infusion
- How many people
- 384 participants
- Where
- 2 sitesVietnam
- Study dates
- 22 Feb 2026to 1 Dec 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 42 years
- Women only
- No healthy volunteers
- Adult
Study population: Women undergoing frozen embryo transfer during the study period.
Who may be able to join
- Women aged 18 - 42 years old
- Scheduled for frozen embryo transfer cycles using hormone replacement therapy protocol or natural cycle protocol (True natural cycles or modified natural cycles)
- Transferred no more than two cleavage embryos or one good-quality blastocyst or no more than two poor-quality blastocysts
Who cannot join
- Having an allergy and contraindications for exogenous hormone administration (e.g., breast cancer, thromboembolic disease)
- Cycles with preimplantation genetic testing, oocyte donation, or in vitro maturation
- Having untreated uterine or adnexal abnormalities (e.g., intrauterine adhesions, unicornuate/ bicornuate/ arcuate uterus, endometrial polyp, large leiomyoma ≥5 cm in diameter, hydrosalpinx, endometrial hyperplasia).
- Use of uterine relaxants or intralipid infusion during the embryo transfer process.
- Use of a GnRH-agonist for downregulation within one month.
- PCOS patients
Trial locations and contacts
2 sites in 1 country. Contact the study team or a site near you to ask about taking part.
Vietnam2 sites, 2 recruiting
- Recruiting
My Duc Phu Nhuan Hospital
Ho Chi Minh City, 70000
Xuyen TH Le, MD, +84945260494, bsxuyen.lth@myduchospital.vn
- Not yet recruiting
IVFMD Phu Nhuan - My Duc Phu Nhuan Hospital
Ho Chi Minh City
About this study
Official title: Effects Of Modified Natural Cycle Protocol Peristalsis And Live Birth In Frozen Embryo Transfer: A Prospective Cohort Study
The uterus is a dynamic muscular organ that undergoes rhythmic, wave-like contractions known as endometrial peristalsis or endometrial waves. This muscular activity, which is an essential component of natural fertility, presents a nuanced and sometimes contradictory role in the context of assisted reproductive treatments. Endometrial peristalsis refers to the frequency, amplitude, and pattern of myometrial contractions occurring in different reproductive phases. These peristalsis play vital roles in sperm transport, embryo migration, and implantation. Clinical and imaging studies suggest that abnormal patterns or excessive contractility at the time of embryo transfer may disrupt endometrial-embryo synchrony, impair implantation, and increase miscarriage risk. However, most evidence on endometrial peristalsis pertains to fresh embryo transfer cycles, natural conceptions, or pathological contexts, such as adenomyosis or fibroids, with limited insights regarding its effects on different endometrial preparation protocols in frozen embryo transfer (FET). Understanding the dynamics of endometrial peristalsis in this context is clinically important, as inappropriate contractile activity could physically expel the embryo or create a non-receptive environment, ultimately reducing the chances of live birth. Despite its theoretical significance, there is a paucity of robust, prospective data correlating endometrial peristalsis patterns measured around the time of FET with different endometrial preparation protocols with subsequent pregnancy outcomes.
Read the detailed description
The uterus is a dynamic muscular organ that undergoes rhythmic, wave-like contractions known as endometrial peristalsis or endometrial waves. This muscular activity, which is an essential component of natural fertility, presents a nuanced and sometimes contradictory role in the context of assisted reproductive treatments. Endometrial peristalsis refers to the frequency, amplitude, and pattern of myometrial contractions occurring in different reproductive phases. These peristalsis play vital roles in sperm transport, embryo migration, and implantation.
Clinical and imaging studies suggest that abnormal patterns or excessive contractility at the time of embryo transfer may disrupt endometrial-embryo synchrony, impair implantation, and increase miscarriage risk. However, most evidence on uterine contractility pertains to fresh embryo transfer cycles, natural conceptions, or pathological contexts, such as adenomyosis or fibroids, with limited insights regarding its effects on different FET protocols. Several studies have demonstrated an inverse relationship between endometrial peristalsis and IVF success. Masroor et al. found that patients with lower endometrial peristaltic wave frequency (<4 waves/min) before embryo transfer had significantly higher chances of clinical pregnancy and live birth compared to those with more frequent peristalsis. Similarly, Chung et al. reported that increased endometrial peristalsis frequency immediately after embryo transfer was linked to reduced live birth rates, suggesting that excessive motility may physically expel the embryo or disturb its implantation. In the prospective cohort study of 292 infertile women, Zhu et al. found that lower uterine peristaltic wave frequency (<3.0 waves/min) before embryo transfer is associated with higher clinical pregnancy rates in both fresh and frozen-thawed embryo transfer cycles. In a study by Vuong et al. on patients with repeated implantation failure, they found that administering atosiban to patients with uterine peristalsis exceeding 16 waves per 4 minutes could improve pregnancy rates.
In recent years, there has been growing interest in performing FET in natural cycles. Natural-cycle FET protocols may better reproduce physiological endocrine and uterine environments than fully artificial, hormone-replacement cycles, potentially influencing uterine contractility patterns, implantation rates, and obstetric outcomes, while also reducing medication burden for ovulatory women. Building on this evidence, the present study will examine the relationship between peri-transfer uterine peristalsis in natural-cycle frozen embryo transfer and subsequent live birth, with the aim of identifying clinically relevant thresholds of contractile activity that could inform individualized embryo-transfer strategies.
- Conditions
- Infertility, Endometrial Peristalsis, Uterine Contraction, Endometrial Waves, Frozen Embryo Transfer (FET), Uterine Peristalsis
- Being tested
- Endometrial peristalsis and hormone measurements
- Keywords
- endometrial peristalsis, uterine contractions, endometrial waves, frozen embryo transfer, natural cycles, artificial cycles
- Medical subject headings
- Infertility
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Endometrial peristalsis and hormone measurementsOther
Time point for measurement
Endometrial peristalsis will be assessed at three specific time points:
- On the second day to the fourth day of the menstrual cycle in the FET cycles.
- The day of hCG trigger, (before progesterone exposure)
- On the day of embryo transfer, immediately prior to the procedure
Hormone measurements
Serum levels of estradiol (E2) and progesterone (P4) will be assessed three times, on the same days as the endometrial peristalsis measurements, using electrochemiluminescence immunoassays. (Elecsys® Estradiol III and Elecsys® Progesterone III, Cobas® e 411, Roche Diagnostics, Germany):
- On the second day to the fourth day of the menstrual cycle in the FET cycles
- The day of hCG trigger
- On the transfer day prior to the procedure.
| Study group | Role | What they receive |
|---|---|---|
| Modified natural cycle | On modified natural cycle, when the mean diameter of the dominant follicle is ≥16 mm, human chorionic gonadotropin (hCG, Ovitrelle® 250 µg; Merck, USA or IVF-C 5000IU, LG Chem, Korea) will be injected to trigger ovulation. Vaginal progesterone (Cyclogest, LD Collins, UK) at a dose of 800 mg per day was started 2 days after hCG injection. Embryo transfer will be scheduled by the time of hCG trigger and embryo stages. Vaginal progesterone administration will be maintained until the day of the pregnancy test. In the event of a positive test result, luteal phase support will be extended until 10 weeks of gestation. Receives: Other: Endometrial peristalsis and hormone measurements |
What is being measured
The primary outcome is the main question the study is designed to answer.
The association between live birth and uterine contraction frequency measured at different time points.
- Live birth was defined as the complete expulsion or extraction from a woman of a product of fertilization, after 22 completed weeks of gestational age; which, after such separation, breathes or shows any other evidence of life, such as heartbeat, umbilical cord pulsation, or definite movement of voluntary muscles, irrespective of whether the umbilical cord has been cut or the placenta is attached. A birth weight of 500 grams or more can be used if gestational age is unknown. Live births refer to the individual newborn; for example, a twin delivery represents two live births.
- Uterine contraction frequency is defined as the number of peristaltic waves per minute.
Measured: • On the second day to the fourth day of the menstrual cycle in the FET cycles. • The day of hCG trigger • On the day of embryo transfer, immediately prior to the procedure
Secondary outcomes (26)
The frequency of endometrial peristalsis at different time points
The frequency of endometrial peristalsis at different time points
Measured: On the second day to the fourth day of the menstrual cycle in the FET cycles. The day of hCG trigger On the day of embryo transfer, immediately prior to the procedure
Live birth rates after the one embryo transfer.
Live birth was defined as the complete expulsion or extraction from a woman of a product of fertilization, after 22 completed weeks of gestational age; which, after such separation, breathes or shows any other evidence of life, such as heartbeat, umbilical cord pulsation, or definite movement of voluntary muscles, irrespective of whether the umbilical cord has been cut or the placenta is attached. A birth weight of 500 grams or more can be used if gestational age is unknown. Live births refer to the individual newborn; for example, a twin delivery represents two live births.
Measured: At delivery
Direction of peristalsis.
Direction of peristalsis is categorized as cervix-to-fundus, fundus-to-cervix, indeterminate, or absent (no contractions observed)
Measured: • On the second day to the fourth day of the menstrual cycle in the FET cycles. • The day of progesterone initiation or LH surge/hCG trigger, (before progesterone exposure) • On the day of embryo transfer, immediately prior to the procedure
The correlation between endometrial peristalsis at different time points
The correlation between endometrial peristalsis at different time points.
Measured: • On the second day to the fourth day of the menstrual cycle in the FET cycles. • The day of progesterone initiation or LH surge/hCG trigger, (before progesterone exposure) • On the day of embryo transfer, immediately prior to the procedure
Positive pregnancy test
Defined as serum human chorionic gonadotropin level ≥ 25 mIU/mL.
Measured: 10-14 days after embryo transfer
Clinical pregnancy
A pregnancy diagnosed by ultrasonographic visualization of one or more gestational sacs or definitive clinical signs of pregnancy. In addition to intra-uterine pregnancy, it includes a clinically documented ectopic pregnancy.
Measured: 4-6 weeks after embryo transfer
Ongoing pregnancy
A pregnancy diagnosed by ultrasonographic or clinical documentation of at least one fetus with a discernible heartbeat at 12 weeks gestation or beyond.
Measured: 12 weeks of gestation or beyond
Implantation rate
The number of gestational sacs observed divided by the number of embryos transferred (usually expressed as a percentage).
Measured: At 4-6 weeks after embryo transfer
Ectopic pregnancy
A pregnancy outside the uterine cavity, diagnosed by ultrasound, surgical visualization, or histopathology.
Measured: Up to 12 weeks after embryo transfer
Miscarriage
Spontaneous loss of a clinical pregnancy before 22 completed weeks of gestational age, in which the embryo(s) or fetus(es) is/are nonviable and is/are not spontaneously absorbed or expelled from the uterus.
Measured: Up to 22 weeks of gestation
Multiple gestations
A pregnancy with more than one embryo or fetus.
Measured: At delivery
Multiple birth
The complete expulsion or extraction from a woman of more than one fetus, after 22 completed weeks of gestational age, irrespective of whether it is a live birth or stillbirth. Births refer to the individual newborn; for example, a twin delivery represents two births.
Measured: At delivery
Mode of delivery
Vaginal delivery, C-section (elective, suspected fetal distress, non-progressive labor).
Measured: At delivery
Birth weight
Weight of the newborn measured right after delivery.
Measured: At delivery
Gestational age at birth
Calculated by gestational age of all live births.
Measured: At delivery
Preterm birth
Defined as delivery at <28, <32, <37 completed weeks. A birth that takes place after 22 weeks and before 37 completed weeks of gestational age.
Measured: At delivery
Gestational diabetes mellitus
A 75-g OGTT, with plasma glucose measurement when the patient is fasting and at 1 and 2 h, at 24-28 weeks of gestation in women not previously diagnosed with diabetes.
Measured: At 24-28 weeks of gestation
Hypertensive disorders of pregnancy
Hypertensive disorders of pregnancy: Pregnancy-induced hypertension, pre-eclampsia (early and late), eclampsia, and HELLP syndrome are defined in the American College of Obstetricians and Gynecologists (ACOG) 2020 g
Measured: Up to delivery
Stillbirth
The death of a fetus before the complete expulsion or extraction from its mother after 28 completed weeks of gestational age. The death is determined by the fact that, after such separation, the fetus does not breathe or show any other evidence of life, such as heartbeat, umbilical cord pulsation, or definite movement of voluntary muscles. Note: It includes deaths occurring during labor.
Measured: Up to delivery
Very low birth weight
Birth weight less than 1.500 g.
Measured: Up to delivery
Low birth weight
Birth weight less than 2.500 g.
Measured: Up to delivery
High birth weight
Implies growth beyond an absolute birth weight, historically 4.000 g or 4.500 g, regardless of the gestational age.
Measured: Up to delivery
Very high birth weight
Birth weight over 4.500 g for women with diabetes, and a threshold of 5000 g for women without diabetes.
Measured: Up to delivery
Major congenital abnormalities
Structural, functional, and genetic anomalies that occur during pregnancy, and are identified antenatally, at birth, or later in life, and require surgical repair of a defect, or are visually evident, or life-threatening, or cause death. Any congenital anomaly will be included as follows definition of congenital abnormalities in Surveillance of Congenital Anomalies by Division of Birth Defects and Developmental Disabilities, NCBDDD, Centers for Disease Control and Prevention (2020).
Measured: Up to delivery
NICU admission
The admission of the newborn to the NICU.
Measured: Up to delivery
Neonatal mortality
Death of a live-born baby within 28 days of birth. This can be divided into early neonatal mortality, if death occurs in the first seven days after birth, and late neonatal if death occurs between 8 and 28 days after delivery.
Measured: Up to delivery
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Jan 2026
- Study start22 Feb 2026
- Primary completion1 Dec 2026 (estimated)
- Study completion1 Dec 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for InfertilityStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 384 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Mỹ Đức Hospital
- Sponsor type
- University, hospital or other
- Collaborators
- My Duc Phu Nhuan Hospital HCMC, Vietnam
- Responsible party
- Sponsor
- Investigators
- Lan N Vuong, MD, PhD, Principal investigator, IVFMD and HOPE Research Center, My Duc Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07358468
- Sponsor's protocol ID
- 18/25/DD-BVMD
- Acronym
- EPFE
- Status last verified
- Mar 2026
- First submitted
- 26 Dec 2025
- Last updated
- 19 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 19 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effects Of Modified Natural Cycle Protocol Peristalsis And Live Birth In Frozen Embryo Transfer: A Prospective Cohort Study
- ClinicalTrials.gov ID
- NCT07358468
- Acronym / sponsor ID
- EPFE / 18/25/DD-BVMD
- Conditions
- Infertility, Endometrial Peristalsis, Uterine Contraction, Endometrial Waves, Frozen Embryo Transfer (FET), Uterine Peristalsis
- Keywords
- endometrial peristalsis, uterine contractions, endometrial waves, frozen embryo transfer, natural cycles, artificial cycles
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 384 participants (estimated)
- Lead sponsor
- Mỹ Đức HospitalUniversity, hospital or other
- Collaborators
- My Duc Phu Nhuan Hospital HCMC, Vietnam
- Study start
- 22 Feb 2026 (actual)
- Primary completion
- 1 Dec 2026 (estimated)
- Study completion
- 1 Dec 2027 (estimated)
- First posted
- 22 Jan 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The uterus is a dynamic muscular organ that undergoes rhythmic, wave-like contractions known as endometrial peristalsis or endometrial waves. This muscular activity, which is an essential component of natural fertility, presents a nuanced and sometimes contradictory role in the context of assisted reproductive treatments. Endometrial peristalsis refers to the frequency, amplitude, and pattern of myometrial contractions occurring in different reproductive phases. These peristalsis play vital roles in sperm transport, embryo migration, and implantation. Clinical and imaging studies suggest that abnormal patterns or excessive contractility at the time of embryo transfer may disrupt endometrial-embryo synchrony, impair implantation, and increase miscarriage risk. However, most evidence on endometrial peristalsis pertains to fresh embryo transfer cycles, natural conceptions, or pathological contexts, such as adenomyosis or fibroids, with limited insights regarding its effects on different endometrial preparation protocols in frozen embryo transfer (FET). Understanding the dynamics of endometrial peristalsis in this context is clinically important, as inappropriate contractile activity could physically expel the embryo or create a non-receptive environment, ultimately reducing the chances of live birth. Despite its theoretical significance, there is a paucity of robust, prospective data correlating endometrial peristalsis patterns measured around the time of FET with different endometrial preparation protocols with subsequent pregnancy outcomes.
Detailed description
The uterus is a dynamic muscular organ that undergoes rhythmic, wave-like contractions known as endometrial peristalsis or endometrial waves. This muscular activity, which is an essential component of natural fertility, presents a nuanced and sometimes contradictory role in the context of assisted reproductive treatments. Endometrial peristalsis refers to the frequency, amplitude, and pattern of myometrial contractions occurring in different reproductive phases. These peristalsis play vital roles in sperm transport, embryo migration, and implantation.
Clinical and imaging studies suggest that abnormal patterns or excessive contractility at the time of embryo transfer may disrupt endometrial-embryo synchrony, impair implantation, and increase miscarriage risk. However, most evidence on uterine contractility pertains to fresh embryo transfer cycles, natural conceptions, or pathological contexts, such as adenomyosis or fibroids, with limited insights regarding its effects on different FET protocols. Several studies have demonstrated an inverse relationship between endometrial peristalsis and IVF success. Masroor et al. found that patients with lower endometrial peristaltic wave frequency (<4 waves/min) before embryo transfer had significantly higher chances of clinical pregnancy and live birth compared to those with more frequent peristalsis. Similarly, Chung et al. reported that increased endometrial peristalsis frequency immediately after embryo transfer was linked to reduced live birth rates, suggesting that excessive motility may physically expel the embryo or disturb its implantation. In the prospective cohort study of 292 infertile women, Zhu et al. found that lower uterine peristaltic wave frequency (<3.0 waves/min) before embryo transfer is associated with higher clinical pregnancy rates in both fresh and frozen-thawed embryo transfer cycles. In a study by Vuong et al. on patients with repeated implantation failure, they found that administering atosiban to patients with uterine peristalsis exceeding 16 waves per 4 minutes could improve pregnancy rates.
In recent years, there has been growing interest in performing FET in natural cycles. Natural-cycle FET protocols may better reproduce physiological endocrine and uterine environments than fully artificial, hormone-replacement cycles, potentially influencing uterine contractility patterns, implantation rates, and obstetric outcomes, while also reducing medication burden for ovulatory women. Building on this evidence, the present study will examine the relationship between peri-transfer uterine peristalsis in natural-cycle frozen embryo transfer and subsequent live birth, with the aim of identifying clinically relevant thresholds of contractile activity that could inform individualized embryo-transfer strategies.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Modified natural cycle | – | Other: Endometrial peristalsis and hormone measurementsOn modified natural cycle, when the mean diameter of the dominant follicle is ≥16 mm, human chorionic gonadotropin (hCG, Ovitrelle® 250 µg; Merck, USA or IVF-C 5000IU, LG Chem, Korea) will be injected to trigger ovulation. Vaginal progesterone (Cyclogest, LD Collins, UK) at a dose of 800 mg per day was started 2 days after hCG injection. Embryo transfer will be scheduled by the time of hCG trigger and embryo stages. Vaginal progesterone administration will be maintained until the day of the pregnancy test. In the event of a positive test result, luteal phase support will be extended until 10 weeks of gestation. |
Who may qualify
- Ages
- 18 to 42 years
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult
- Study population
- Women undergoing frozen embryo transfer during the study period.
Key inclusion criteria (3 listed)
- Women aged 18 - 42 years old
- Scheduled for frozen embryo transfer cycles using hormone replacement therapy protocol or natural cycle protocol (True natural cycles or modified natural cycles)
- Transferred no more than two cleavage embryos or one good-quality blastocyst or no more than two poor-quality blastocysts
Key exclusion criteria (6 listed)
- Having an allergy and contraindications for exogenous hormone administration (e.g., breast cancer, thromboembolic disease)
- Cycles with preimplantation genetic testing, oocyte donation, or in vitro maturation
- Having untreated uterine or adnexal abnormalities (e.g., intrauterine adhesions, unicornuate/ bicornuate/ arcuate uterus, endometrial polyp, large leiomyoma ≥5 cm in diameter, hydrosalpinx, endometrial hyperplasia).
- Use of uterine relaxants or intralipid infusion during the embryo transfer process.
- Use of a GnRH-agonist for downregulation within one month.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Endometrial peristalsis and hormone measurementsTime point for measurement Endometrial peristalsis will be assessed at three specific time points: * On the second day to the fourth day of the menstrual cycle in the FET cycles. * The day of hCG trigger, (before progesterone exposure) * On the day of embryo transfer, immediately prior to the procedure Hormone measurements Serum levels of estradiol (E2) and progesterone (P4) will be assessed three times, on the same days as the endometrial peristalsis measurements, using electrochemiluminescence immunoassays. (Elecsys® Estradiol III and Elecsys® Progesterone III, Cobas® e 411, Roche Diagnostics, Germany): * On the second day to the fourth day of the menstrual cycle in the FET cycles * The day of hCG trigger * On the transfer day prior to the procedure. | Other | Modified natural cycle |
Primary outcome
The association between live birth and uterine contraction frequency measured at different time points.
Time frame: • On the second day to the fourth day of the menstrual cycle in the FET cycles. • The day of hCG trigger • On the day of embryo transfer, immediately prior to the procedure
* Live birth was defined as the complete expulsion or extraction from a woman of a product of fertilization, after 22 completed weeks of gestational age; which, after such separation, breathes or shows any other evidence of life, such as heartbeat, umbilical cord pulsation, or definite movement of voluntary muscles, irrespective of whether the umbilical cord has been cut or the placenta is attached. A birth weight of 500 grams or more can be used if gestational age is unknown. Live births refer to the individual newborn; for example, a twin delivery represents two live births. * Uterine contraction frequency is defined as the number of peristaltic waves per minute.
26 secondary outcomes
The frequency of endometrial peristalsis at different time points
Time frame: On the second day to the fourth day of the menstrual cycle in the FET cycles. The day of hCG trigger On the day of embryo transfer, immediately prior to the procedure
Live birth rates after the one embryo transfer.
Time frame: At delivery
Direction of peristalsis.
Time frame: • On the second day to the fourth day of the menstrual cycle in the FET cycles. • The day of progesterone initiation or LH surge/hCG trigger, (before progesterone exposure) • On the day of embryo transfer, immediately prior to the procedure
The correlation between endometrial peristalsis at different time points
Time frame: • On the second day to the fourth day of the menstrual cycle in the FET cycles. • The day of progesterone initiation or LH surge/hCG trigger, (before progesterone exposure) • On the day of embryo transfer, immediately prior to the procedure
Positive pregnancy test
Time frame: 10-14 days after embryo transfer
Clinical pregnancy
Time frame: 4-6 weeks after embryo transfer
Ongoing pregnancy
Time frame: 12 weeks of gestation or beyond
Implantation rate
Time frame: At 4-6 weeks after embryo transfer
Ectopic pregnancy
Time frame: Up to 12 weeks after embryo transfer
Miscarriage
Time frame: Up to 22 weeks of gestation
Multiple gestations
Time frame: At delivery
Multiple birth
Time frame: At delivery
Mode of delivery
Time frame: At delivery
Birth weight
Time frame: At delivery
Gestational age at birth
Time frame: At delivery
Preterm birth
Time frame: At delivery
Gestational diabetes mellitus
Time frame: At 24-28 weeks of gestation
Hypertensive disorders of pregnancy
Time frame: Up to delivery
Stillbirth
Time frame: Up to delivery
Very low birth weight
Time frame: Up to delivery
Low birth weight
Time frame: Up to delivery
High birth weight
Time frame: Up to delivery
Very high birth weight
Time frame: Up to delivery
Major congenital abnormalities
Time frame: Up to delivery
NICU admission
Time frame: Up to delivery
Neonatal mortality
Time frame: Up to delivery
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 19 Aug 2026.
- Individual participant dataSharing planned: No
Related trials for Infertility
RecruitingObservational study
International Pilot Study for Dual Non-invasive Assesment of Embryo Development
Infertility
Active, not recruitingObservational study
Retrieval of Sperm From Men With Azoospermia Using Ultrasound-guided Rete Testis Aspiration
Azoospermia, Nonobstructive, Infertility, Male
Not yet recruiting
Spinery Basivertebral Nerve Ablation for Vertebrogenic Chronic Low Back Pain
Low Back Pain, Chronic Low Back Pain (CLBP)
RecruitingObservational study
Impact of Infertility on the Sexual Sphere in Couples Undergoing Assisted Reproduction
Sexual Health Quality of Life, Infertile Patients
RecruitingObservational study
Pilot Study of Discarded Blastocysts
Infertility (IVF Patients)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Lan N Vuong, MD, PhD principal investigator
IVFMD and HOPE Research Center, My Duc Hospital
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Infertility and Endometrial Peristalsis, run by Mỹ Đức Hospital at 2 sites in Vietnam.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 19 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in Vietnam. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Xuyen Thi Ha Le, MD (+84945260494, bsxuyen.lth@myduchospital.vn), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The association between live birth and uterine contraction frequency measured at different time points. (time frame: • On the second day to the fourth day of the menstrual cycle in the FET cycles. • The day of hCG trigger • On the day of embryo transfer, immediately prior to the procedure). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Aug 2026.